Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 8/2020

01-08-2020 | Gastric Cancer | Original Article

Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER Database

Authors: Huafu Li, Zhewei Wei, Chunming Wang, Wei Chen, Yulong He, Changhua Zhang

Published in: Journal of Gastrointestinal Surgery | Issue 8/2020

Login to get access

Abstract

Objectives

To evaluate gender differences in initial presentation, pathology and outcomes with GC (GC).

Methods

The 1973–2013 Surveillance Epidemiology and End Results (SEER) 17-registry database was analysed for renal tumours from 1973 to 2013 coded as primary site “stomach”. After various exclusions, a final study group of 99,922 cases with complete data was obtained. Demographic variables analysed included age, sex, marital status and race. Tumour variables included size, stage at diagnosis, grade, primary site, treatment and histology. Primary outcome variables included overall survival (OS) and cancer-specific survival (CSS).

Results

Overall, 96,501 gastric cancer patients were identified. Of those, 34,862 (36.2%) were women. For woman, log-rank test showed that OS and CSS were significantly longer in man (p < 0.0001). In Cox regression analysis, woman was associated with a significantly improved OS [(HR of death in 1973 to 2003 = 0.87, 95% CI = 0.85–0.89, P < 0.001) (HR of death in 2004 to 2013 = 0.94, 95% CI = 0.91–0.97, P < 0.001)] and cancer-specific survival [(HR of death in 1973 to 2003 = 0.90, 95% CI = 0.87–0.92, P < 0.001) (HR of death in 2004 to 2013 = 0.90, 95% CI = 0.87–0.93, P < 0.001)]. When performing a Kaplan-Meier curve analysis after propensity score matching, gender persisted to be a significant survival of woman for OS and CSS.

Conclusions

Men present with larger, higher stage, higher grade GC than women. OS and CSS are better in women, which is significantly different.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. Jan-Feb 2014;64(1):9–29. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. Jan-Feb 2014;64(1):9–29.
2.
go back to reference Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Japanese journal of clinical oncology. Nov 2013;43(11):1157–1158.PubMed Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Japanese journal of clinical oncology. Nov 2013;43(11):1157–1158.PubMed
3.
go back to reference Rawicz-Pruszynski K, van Sandick JW, Mielko J, Cisel B, Polkowski WP. Current challenges in gastric cancer surgery: European perspective. Surgical oncology. Dec 2018;27(4):650–656.PubMed Rawicz-Pruszynski K, van Sandick JW, Mielko J, Cisel B, Polkowski WP. Current challenges in gastric cancer surgery: European perspective. Surgical oncology. Dec 2018;27(4):650–656.PubMed
4.
go back to reference Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. May 2014;23(5):700–713. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. May 2014;23(5):700–713.
5.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer (Oxford, England : 1990). Apr 2013;49(6):1374–1403. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer (Oxford, England : 1990). Apr 2013;49(6):1374–1403.
6.
go back to reference Leoncini E, Vukovic V, Cadoni G, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. European journal of epidemiology. Dec 2018;33(12):1205–1218.PubMedPubMedCentral Leoncini E, Vukovic V, Cadoni G, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. European journal of epidemiology. Dec 2018;33(12):1205–1218.PubMedPubMedCentral
7.
go back to reference Uhlig A, Seif Amir Hosseini A, Simon J, et al. Gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis The Journal of urology. Jul 2018;200(1):48–60.PubMed Uhlig A, Seif Amir Hosseini A, Simon J, et al. Gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis The Journal of urology. Jul 2018;200(1):48–60.PubMed
8.
go back to reference Fitchett EJA, Seale AC, Vergnano S, et al. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. The Lancet. Infectious diseases. Oct 2016;16(10):e202-e213.PubMed Fitchett EJA, Seale AC, Vergnano S, et al. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. The Lancet. Infectious diseases. Oct 2016;16(10):e202-e213.PubMed
9.
go back to reference Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. European urology. Jul 2008;54(1):133–140.PubMed Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. European urology. Jul 2008;54(1):133–140.PubMed
10.
go back to reference Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. Jun 2000;55(6):876–880.PubMed Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. Jun 2000;55(6):876–880.PubMed
11.
go back to reference Song M, Kang D, Yang JJ, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. Jul 2015;18(3):580–589. Song M, Kang D, Yang JJ, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. Jul 2015;18(3):580–589.
12.
go back to reference Kim HW, Kim JH, Lim BJ, et al. Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer. Annals of surgical oncology. Dec 2016;23(13):4344–4351.PubMed Kim HW, Kim JH, Lim BJ, et al. Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer. Annals of surgical oncology. Dec 2016;23(13):4344–4351.PubMed
13.
go back to reference Yang Y, Wang G, He J, et al. Gender differences in colorectal cancer survival: a meta-analysis. International journal of cancer. Nov 15 2017;141(10):1942–1949.PubMed Yang Y, Wang G, He J, et al. Gender differences in colorectal cancer survival: a meta-analysis. International journal of cancer. Nov 15 2017;141(10):1942–1949.PubMed
14.
go back to reference Gan L, He J, Zhang X, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC cancer. Dec 2 2012;12:566.PubMedPubMedCentral Gan L, He J, Zhang X, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC cancer. Dec 2 2012;12:566.PubMedPubMedCentral
15.
go back to reference Fang Z, Zhang T, Dizeyi N, et al. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. The Journal of biological chemistry.Jan 13 2012;287(3):2090–2098.PubMed Fang Z, Zhang T, Dizeyi N, et al. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. The Journal of biological chemistry.Jan 13 2012;287(3):2090–2098.PubMed
16.
go back to reference Liu X, Gao Y, Ye H, et al. Positive feedback loop mediated by protein phosphatase 1alpha mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic acids research. Apr 20 2017;45(7):3738–3751.PubMedPubMedCentral Liu X, Gao Y, Ye H, et al. Positive feedback loop mediated by protein phosphatase 1alpha mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic acids research. Apr 20 2017;45(7):3738–3751.PubMedPubMedCentral
17.
go back to reference Yoshida S, Aihara K, Ikeda Y, et al. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. Jul 2 2013;128(1):60–71.PubMedPubMedCentral Yoshida S, Aihara K, Ikeda Y, et al. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. Jul 2 2013;128(1):60–71.PubMedPubMedCentral
18.
go back to reference Ozguroglu M, Demir G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. Aug 1 1999;86(3):547–549.PubMed Ozguroglu M, Demir G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. Aug 1 1999;86(3):547–549.PubMed
19.
go back to reference Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. The Journal of pathology. Jan 1999;187(2):237–241.PubMed Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. The Journal of pathology. Jan 1999;187(2):237–241.PubMed
20.
go back to reference Wu W, Karelia D, Pramanik K, et al. Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. Molecular carcinogenesis. Aug 2018;57(8):1055–1066.PubMed Wu W, Karelia D, Pramanik K, et al. Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. Molecular carcinogenesis. Aug 2018;57(8):1055–1066.PubMed
21.
go back to reference Feng H, Cheng AS, Tsang DP, et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. The Journal of clinical investigation. Aug 2011;121(8):3159–3175.PubMedPubMedCentral Feng H, Cheng AS, Tsang DP, et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. The Journal of clinical investigation. Aug 2011;121(8):3159–3175.PubMedPubMedCentral
22.
go back to reference Grumolato L, Liu G, Haremaki T, et al. beta-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS genetics. 2013;9(8):e1003603.PubMedPubMedCentral Grumolato L, Liu G, Haremaki T, et al. beta-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS genetics. 2013;9(8):e1003603.PubMedPubMedCentral
23.
go back to reference Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Statistics in medicine. Sep 10 2010;29(20):2137–2148.PubMedPubMedCentral Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Statistics in medicine. Sep 10 2010;29(20):2137–2148.PubMedPubMedCentral
Metadata
Title
Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER Database
Authors
Huafu Li
Zhewei Wei
Chunming Wang
Wei Chen
Yulong He
Changhua Zhang
Publication date
01-08-2020
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 8/2020
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04304-y

Other articles of this Issue 8/2020

Journal of Gastrointestinal Surgery 8/2020 Go to the issue